🔎 Neoadjuvant and adjuvant EV/pembro was associated with greater ctDNA clearance than cisplatin-based chemotherapy among patients with cisplatin-eligible MIBC, according to an expl

GU Oncology Now· @GUOncologyNow · X·2026-10-24 03:30· 2 天前评分70

正文 · 原文

🔎 Neoadjuvant and adjuvant EV/pembro was associated with greater ctDNA clearance than cisplatin-based chemotherapy among patients with cisplatin-eligible MIBC, according to an exploratory analysis of the phase 3 KEYNOTE-B15/EV-304 trial presented at #ESMO26: https://buff.ly/ujrrmwx

69 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

4734O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上

ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin

https://esmocongress.esmo.org

NCT04700124NCT04700124按 - **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) 对上

- **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

https://esmocongress.esmo.org

来源：GU Oncology Now · x.com